Neurology Flashcards
Craniotomy
Removing part of bone from skull to expose brain eg. to remove tumour. Bone flap is temporarily removed and then immediately replaced after brain surgery.
Craniectomy
Portion of skull removed to help relieve pressure on brain. Bone fragment not immediately put back into place but rather kept (eg in abdomen to keep the tissue alive) and then replaced in a future surgery once pressure recovers. Occasionally bone fragment is simply discarded.
Aphasia
- Impairment of language, affecting the production or comprehension of speech and the ability to read/write.
- Often due to stroke but can also arise from other brain injuries eg. head trauma, tumours, infection.
- Can be temporary or permanent
Global aphasia
- most severe type of aphasia
- patients ca produce few recognisable words and understand little or no spoken language
- Cannot read or write
Broca’s aphasia
- Non-fluent aphasia
- Speech output is severly reduced and limited, vocabulary is limited and formation of sounds is laborious and clumsy. Patient often halts during speech
- Patient may understand speech well and can read but be limited in writing
- Often complains that they can’t “find the words”
Mixed non-fluent aphasia
- Sparse and effortful spech, resembling sever Broca’s aphasia
- However, unlike Broca’s, they struggle to understand spech and cannot read or write
Wernicke’s aphasia
- Fluent aphasia
- Cannot grasp meaning of spoken words
- Can still produce connected speech but sentences do not make sense and often include irrelevant words which don’t make sense together
- Reading and writing often impaired
Myasthenia gravis, it symptoms an risk factors
- Chronic autoimmune disorder of post-synaptic membrane at NMJ in skeletal muscle
- Characterised by muscle weakness- increases during exercise, improves on rest (muscle strength fatigability)
- Commonly presents with ptosis, diplopia, oropharyngeal (dysphagia) and appendicular (limb) weakness and SOB
- Risk factors- family history of autoimmune disorders, genetic markers, cancer-targeted therapy
Myasthenia gravis- pathophysiology and investigations
- Circulating antibodies against the nicotinic acetylcholine receptor (AChR) or associated proteins impair neuromuscular transmission
- Elevated serum levels of antibodies against AChR or muscle-specific tyrosine kinase (MuSK) usually present (serum antibody analysis)
- Could also have antibodies against LRP4, collagen Q and cortactin
- Clinical electrophysiology results include decrease in response on repetitive nerve stimulation
- Could also perform serial pulmonary function tests
Myasthenia gravis- treatment
- Pyridostigmine (anticholinesterase inhibitor)
- Immunotherapy (corticosteroid, immunosuppressants), efgartigimod alfa
Myasthenic crisis
Exacerbation necessitating mechanical ventilation and acute treatment with IV immunoglobulin or plama exchange
Acetylcholine
- excitatory neurotransmitter
- main neurotransmitter of the parasympathetic nervous system
Alzheimer’s disease and presentation
- Chronic, progressive neurodegenerative disorder
- Characterised by a global, non-reversible impairment in cerebral functioning
- Deteriotating course over 8-10 years
Alzheimer’s disease symptoms and risk factors
- Memory loss, disorientation, slight dysphasia, mood changes, constructional dyspraxia, prospagnosia (inability to recognise faces)
- Risk factors- advanced age, family history, genetics, DOwn’s syndrome
- May co-exist wtith vascular dementia= mixed ementia
Alzheimer’s disease- investigations
- Bedside cognitive testing: MMSE is standard (but take into account education and language), MoCA (fast but limited as it only detects MCI)
- FBC- rules out anaemia
- Metabolic panel- excludes abnormal sodium, calcium, glucose
- Serum TSH- rules out hyperthyroid or hypothyroid-associated dementia
- Serum B12- rules out vitamin B12 deficiency-induced dementia
- Urine drug screen- rules out recreational drug use
- CT- excludes tumours, vascular disease etc
- MRI- may display generalised atrophy with medial temporal lobe and later parietal predominance associated with the disease
Alzheimer’s disease- treatment
- Supportive treatment- care support
- (Anti)cholinesterase inhibitor eg donepezil
- Switch to or add memantine in severe disease (NMDA antagonist)